167 results about "Chondrocyte" patented technology

The present application relates to chondrocyte compositions and kits comprising morselized cartilage tissue particles and a biodegradable matrix. Applications and methods of using the chondrocyte composition for cartilage grafts, repairing cartilage injuries and defects, and joint repair are provided.

The invention relates to an application of a CTHRC1 inhibitor in preparation of a medicine for preventing and / or treating arthritis. Specifically, the invention provides application of an inhibitor or an antagonist of a CTHRC1 gene or a protein thereof, the inhibitor or the antagonist is used for preparing a composition or a preparation, and the composition or the preparation is used for (a) preventing and / or treating arthritis-related diseases; and / or (b) inhibiting cartilage cell senescence.

The invention discloses a composition for promoting cartilage cell proliferation and cartilage repair. The composition comprises a combination of a small molecule cartilage extract and collagen peptide, the average molecular weight of the small molecular cartilage extract is less than or equal to 5000 Da, and the average molecular weight of the collagen peptide is 2000 Da to 4000 Da; the composition is prepared by the following method: (1) cleaning and crushing animal cartilage, performing primary depolymerization by using protease, performing microwave-assisted protease secondary depolymerization, and performing membrane filtration to obtain a small molecular cartilage extract of which the average molecular weight is less than or equal to 5000 Da; and (2) mixing the small molecular cartilage extract obtained in the step (1) with collagen peptide with the average molecular weight of 2000 Da to 4000 Da to obtain the composition. Under the same mass concentration, compared with single-component collagen peptide, cartilage extract or UC-II, the collagen peptide-cartilage extract combination has more outstanding inflammation inhibition effect and cartilage repair effect.

The invention discloses a gelatin-hyaluronic acid injectable hydrogel drug-carrying nanoparticle composite material as well as a preparation method and application thereof, relates to the technical field of biomedicine, and solves the problems that in the prior art, existing drugs for treating cartilage related diseases are difficult to deliver; the chronic inflammatory response in the articular cavity cannot be effectively controlled and cartilage cells cannot be protected at the same time, so that the application effect of the medicine is limited. The preparation method disclosed by the invention comprises the following steps: S1, obtaining a carnosine modified hyaluronic acid derivative Car-HA; s2, preparing nano particles (FNPs) loaded with fenofibrate; and S3, mixing the gelatin solution containing the FNPs with a Car-HA solution, adding transglutaminase into the mixed system, and carrying out an enzymatic cross-linking reaction to form the hydrogel FNPs-GelHA with a stable network structure. The CarHA and FNPs synergistic hydrogel strategy provided by the invention has good structural adjustability and drug adaptability, is suitable for delivery of various anti-inflammatory, anti-oxidation and cartilage repair drugs, and can be widely applied to local precise treatment of cartilage related diseases.

The invention relates to a diatomic iron-iron site nano-enzyme constructed by relieving oxidative stress and cartilage degeneration and used for targeted osteoarthritis treatment. According to the invention, a nitrogen-doped porous carbon anchored diatomic iron nano enzyme catalyst (Fe2-NCs) with Fe-Fe dimer coordination is developed by using a'subject-object 'strategy. The Fe2-NCs protect cartilage cells from oxidative stress induced apoptosis by modulating ROS and active nitrogen species (RNS) and promoting O2 release. In addition, Fe2-NCs restores mitochondrial function by inhibiting NOX4 expression, improving ATP production, and normalizing COXIV levels. In an in-vivo OA model, the Fe2-NCs can reduce the expression of a pro-inflammatory medium COX-2 through an NF-kappa B signal channel, inhibit the up-regulation of MMP-13 and delay the degradation of type II collagen. The invention provides a new theoretical framework and methodological approach for the treatment of osteoarthritis, and has important clinical and scientific significance.

The invention relates to the technical field of recombinant proteins, and relates to a recombinant XII type collagen as well as a preparation method and application thereof. The recombinant XII type collagen is formed by connecting 5-30 repetitive units in series, and the amino acid sequence of each repetitive unit is as shown in SEQ ID NO: 1. The nucleic acid molecule is used for coding the recombinant XII type collagen; a vector comprises the nucleic acid molecule. According to the invention, a nucleotide sequence for coding the amino acid sequence is inserted into a vector to obtain a recombinant plasmid vector, then the recombinant plasmid vector is introduced into a host cell for culture, and then separation and purification are carried out to obtain the recombinant XII type collagen. The recombinant XII type collagen provided by the invention is easy to obtain, can realize efficient secretory expression, and meets the requirements of industrial production; the biological activity is good, and the proliferation and migration of human immortalized cartilage cells can be promoted.

The invention relates to a tissue engineering trachea, which combines an additive manufacturing technology with a biological material, simulates the form and the function of a natural gas pipe, designs a cartilage-fiber alternating ring structure and a bionic fiber band structure, and designs a unique blood supply channel in a fiber section. The trachea fiber section is composed of hydrogel with a hierarchical porous structure, and a circumferential blood vessel channel and a radial blood vessel pore channel are designed in the hydrogel so as to promote ingrowth and growth of new blood vessels and optimize the blood supply reconstruction process. The tracheal cartilage section is made into a C-shaped cartilage ring with cartilage cells through a biological printing technology, and necessary mechanical support is provided. The fiber segment and the cartilage segment are effectively integrated through chemical bonds of functional groups to ensure stable connection of the two. Partitioned construction of fibers and cartilage is achieved through the biological 3D printing technology, the bionic tissue engineering trachea is formed in a modular construction-integrated assembly mode, it is verified that repairing and reconstruction of multiple types of tissue bionic tracheas can be achieved, and an innovative solution is provided for tracheal injuries.

The embodiment of the invention discloses a method for constructing a cartilage micro-tissue by compounding an extracellular matrix with a vascular matrix component and application. The method comprises the following steps: preparing a porcine decellularized cartilage extracellular matrix; generating a cartilage extracellular matrix suspension; carrying out screening treatment on the cartilage extracellular matrix suspension; preparing a porcine acellular cartilage extracellular matrix microcarrier; preparing a target suspension of a common system from the porcine acellular cartilage extracellular matrix microcarrier and vascular matrix component cells, and transferring the target suspension to a bionic floating microenvironment of a shaker bioreactor for dynamic culture; carrying out culture treatment on the porcine acellular cartilage extracellular matrix microcarrier; and taking out the cell-loaded porcine decellularized cartilage extracellular matrix microcarrier from the cultured and treated porcine decellularized cartilage extracellular matrix microcarrier as the constructed cartilage micro-tissue. According to the embodiment, the condition of secondary injury to a user can be improved and reduced, the repairing effect is improved, and the adaptability of the constructed cartilage micro-tissue is improved.

The invention provides a developmental growth plate layered stent as well as a preparation method and application thereof, and belongs to the technical field of bone tissue engineering materials. The developmental growth plate layered stent provided by the invention is divided into three layers, the upper layer is a cartilage cell layer, the middle layer is a blood vessel barrier layer, and the lower layer is an ossification layer. The blood vessel barrier layer can be used as biological glue to bond the upper layer and the lower layer, so that the composite stent is stable in structure and not easy to break; the upper layer contains bone marrow mesenchymal stem cells (BMSCs), and the middle layer and the lower layer are free of cells. Under the condition of in-vitro chondrogenesis induction culture, the BMSCs on the upper layer can penetrate through the middle layer and be colonized on the lower layer, and in the process, part of the BMSCs can be differentiated into cartilage cells. The middle layer containing the platelet reaction protein 1 (TSP1) has a specific intervention effect on cell migration, which is expressed by inhibiting the migration of vascular endothelial cells, but has no influence on the migration of the BMSCs.

The present invention relates to CD73 + CD44 + , CD90 + A method for generating a population of mesenchymal stromal cells (MSCs) is provided. + CD44 + , CD90 + MSCs are used in methods to generate terminally differentiated osteogenic, adipogenic, and chondrogenic cells from pluripotent stem cells (PSCs), which involve the use of a single agent, a WNT signaling pathway activator (e.g., a GSK3β inhibitor), in adherent cultures of PSCs.

The application discloses a functional composition for improving bone and joint health, a conditioner and application. The functional composition comprises a first active component and a second active component; the first active component comprises elastin peptide, haematococcus pluvialis and ergothioneine; and the second active component comprises one or more of houttuynia cordata and non-denatured type II collagen. The application realizes the protection effect on joint, cartilage and bone health by scientific matching of the components and synergistically improving the glycosaminoglycan level in chondrocytes and the osteocalcin level in osteoblasts. Meanwhile, the components in the functional composition for improving bone and joint health are natural and have good biocompatibility, and have no obvious side effects, so that the application provides a kind of drug or a substitute for the treatment and prevention of bone diseases.

The present invention provides an injectable magnesium-loaded lipid-based super-lubricating hydrogel microsphere, an articular cavity injection formulation, and a preparation method therefor. The method comprises the following steps: S1, preparing a magnesium-loaded multilamellar vesicular liposome suspension containing magnesium ions; S2, preparing an uncrosslinked magnesium-containing hydrogel; and S3, mixing the magnesium-loaded multilamellar vesicular liposome suspension with the magnesium-containing hydrogel to prepare hydrogel droplets, and carrying out crosslinking to form the magnesium-loaded lipid-based super-lubricating hydrogel microspheres. According to the present invention, the magnesium loading capacity of the lipid-based super-lubricating hydrogel microspheres can be greatly improved; on one hand, the biological function provided by the magnesium ions can be greatly prolonged, that is, the repair of cartilage by synovial liquid progenitor cells is continuously promoted; and on the other hand, the intrinsic lubricating effect of the lipid-based super-lubricating hydrogel microspheres can mitigate the further wear of newly formed cartilage; in addition, the magnesium ions can significantly promote the expression of PRG4 in chondrocytes, which not only facilitates the maintenance of chondrocyte homeostasis, but also further enhances articular lubrication.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of oleanolic acid in promoting chondrogenic differentiation of chondrocytes. This invention discovers that oleanolic acid promotes the expression of proteoglycans and calcium deposition in ATDC5 cells undergoing chondrogenic differentiation, and also promotes the expression of ATDC5 cell chondrogenic differentiation markers. Therefore, it has the potential to be formulated into a drug that can promote chondrogenic differentiation of chondrocytes, thereby promoting cartilage repair and regeneration for the treatment of osteoarthritis and rheumatoid arthritis.

The application belongs to the technical field of biomedical materials, and discloses a collagen-based double-network porous hydrogel scaffold capable of recruiting endogenous stem cells and a construction method and application thereof. The scaffold takes collagen II (Col-II) and oxidized methyl acrylated hyaluronic acid (AHAMA) as an organic phase, and is constructed into a physical / chemical double-network structure through Schiff base dynamic crosslinking and ultraviolet light-induced methacryl radical polymerization. An air-in-water emulsion template method is used to form a through-porous structure, and 5' aldehyde-modified nucleic acid aptamer Apt19S is anchored in the scaffold network to achieve specific recruitment of endogenous pluripotent stem cells. The scaffold has excellent mechanical properties, a biomimetic extracellular matrix microenvironment and a targeted stem cell recruitment function, can effectively promote the directional differentiation of stem cells into chondrocytes, avoids the immune rejection and ethical issues caused by exogenous stem cell transplantation, and is suitable for the field of articular cartilage defect repair.

The present invention relates to a method for producing cartilage tissue by selecting and choosing from chondrocytes or spheroids, and use thereof as pharmaceutical composition, medicinal product or transplant. In particular, the invention relates to markers for identifying suitable chondrocytes for producing cartilage tissue, in particular for the purpose of transplantation.

This invention provides the application of a composition in the preparation of drugs for osteoarthritis, belonging to the field of arthritis technology. The composition comprises tofu glycosides, N-acetylcysteine, seaweed peptides, and PDGF. The combination of these drugs significantly enhances the chondrogenic differentiation and migration capacity of chondrocyte stem cells under inflammatory conditions. Furthermore, in an SD rat knee osteoarthritis model, chondrocyte stem cells treated with the enhanced culture medium reduced the Wakitani histological score from 8.83 to 2.17±0.98, demonstrating a superior repair effect compared to traditional methods. Therefore, this invention provides a foundation for the efficient treatment of osteoarthritis.

The invention relates to an ROS-responsive macrophage-chondrocyte dual-targeting nano-micelle and a preparation method and application thereof, HA capable of targeting and highly expressing CD44 cells is taken as a carrier skeleton, chemical coupling with TK and CUR is carried out in sequence, self-assembly is carried out through intermolecular force to form a stable nano-micelle, and drugs JPH203 and KGN are entrapped at the same time, so that efficient loading and targeting delivery are realized. The HA can be specifically combined with RAW264.7 macrophages and articular cartilage cells for highly expressing a CD44 receptor in an inflammatory state, and is actively delivered in a targeting manner. The ROS response characteristic of TK is utilized, oxidative fracture is carried out in an OA high ROS microenvironment, and micelles are triggered to disintegrate and release drugs accurately. The released JPH203 can inhibit an inflammatory mTOR pathway and effectively resist inflammation, and KGN is beneficial to promoting cartilage cell proliferation and effectively collecting and promoting differentiation of mesenchymal stem cells into cartilage cells, so that in-situ cartilage regeneration is realized, and a more efficient solution with low side effects is provided for osteoarthritis treatment.

The present application relates to the field of eggshell membrane peptide, in order to solve the problem that the proportion of polypeptide with main function of anti-inflammatory effect is low in the eggshell membrane peptide product obtained by hydrolysis of existing eggshell membrane, provide an eggshell membrane peptide and a preparation method thereof, and an application of the eggshell membrane peptide in preparation of anti-inflammatory drugs, comprising: S100, after adding eggshell membrane powder into pure water, adjusting pH, then adding pepsin, enzymolysis for 2-5h, and the enzymolysis temperature is 35-38 DEG C, to obtain a first mixture; S200, the first mixture is subjected to enzyme inactivation process and ultrafiltration process to obtain a first hydrolysate and a first ultrafiltrate; S300, after adjusting the pH value of the first ultrafiltrate to 8-9, adding alkaline protease, enzymolysis for 6-10h, and the enzymolysis temperature is 36-38 DEG C, to obtain a second mixture; S400, the second mixture is subjected to ultrafiltration process to obtain a second ultrafiltrate and a second hydrolysate; S500, after drying the second hydrolysate, a first polypeptide composition is obtained. The present application explores the effect of different hydrolysate components on chondrocyte anti-inflammatory, and screens out eggshell membrane peptides with better effect.

Nanoparticles suitable for delivery of a cargo to a chondrocyte, and targeting peptides comprising a chondrocyte targeting sequence, are provided. Further provided are uses of the nanoparticles and targeting peptides, for example, in treating a joint or cartilage disease or disorder.

This invention relates to the field of biomedical materials, providing non-denatured type II collagen ultrafine powder with cartilage tissue-targeted growth and structural repair functions, its bioactivity preservation preparation method, and its application in joints. The ultrafine powder has an average particle size of 0.5-50 μm, a triple helix structure integrity rate of not less than 85%, a thermal denaturation temperature of 38-48℃, and retains chondrocyte binding domains CB10, CB11, and MMP cleavage sites. The preparation method includes raw material pretreatment, time-limited enzymatic hydrolysis, graded purification, and ultra-low temperature ball milling. The product can be used for the repair and treatment of cartilage degenerative diseases such as osteoarthritis and cartilage damage.

The invention belongs to the technical field of biological medicine, and particularly relates to a small-molecule exosome-loaded composition based on bone marrow mesenchymal stem cells and application of the small-molecule exosome-loaded composition. The invention discloses the treatment effect of squalene on osteoarthritis for the first time, and further prepares the squalene-loaded bone marrow mesenchymal stem cell exosome. An in-vitro cell experiment and a model animal experiment prove that the composition has a synergistic treatment effect on osteoarthritis. In-vitro tests prove that the squalene-loaded mesenchymal stem cell exosome can improve the survival rate of inflammatory cartilage cells, inhibit release of proinflammatory factors and restore expression of repair factors. Model animal experiments prove that the squalene-loaded mesenchymal stem cell exosome has the effects of resisting inflammation, easing pain and protecting cartilage in the treatment of osteoarthritis.

The present invention discloses the use of Avn Anthramides C (Avn C) as an inducer of chondrocytic differentiation in Mesenchymal Stem Cells (MSCs), providing a promising approach for regenerative cartilage therapy. By employing Avn C treatment, MSCs exhibit enhanced chondrocytic differentiation and elevated expression of key specific chondrogenic extracellular matrix (ECM) factors, notably Collagen Type II (COL2A1). Furthermore, when Avn C is used in combination with Chondroitin Sulfate (CS), a synergistic effect is observed, leading to upregulation of the transcriptional activity state of SOX9, a key regulator of chondrogenesis. The disclosed invention shows significant improvements in mRNA gene expression (ACAN, LRP1, SOX9), cellular protein levels (COL2A1, SOX9, LRP1), and functional outcomes, as evidenced by the secretion of extracellular matrix proteins (FSTL-1, BGH3, CO1A1, CO1A2, and CO3A1).

This invention relates to a method of treating a joint and / or bone disease, slowing progression of a reduction in bone mass, increasing osteoblast formation, decreasing osteoclast formation, and / or reducing osteocyte death, slowing progression of a reduction in joint mobility and / or function, slowing progression of a reduction in cartilage, and / or reducing chondrocyte senescence and / or death by administering a therapeutically effective amount of a SIRT6 activator, optionally with nicotinamide adenine dinucleotide (NAD+) and / or an NAD+ precursor.

The invention discloses application of chlorella in preparation of a medicine for treating osteoarthritis, in-vivo experiments and in-vitro experiments prove that chlorella can maintain a chondrocyte metabolism steady state, inhibit expression of chondrocyte extracellular matrix catabolism-related genes and proteins, and inhibit osteoarthritis. The expression of genes and proteins related to chondrocyte extracellular matrix anabolism is promoted, and by injecting a chlorella solution into a knee joint cavity, the effects of relieving and improving OA pain are achieved; furthermore, polydopamine is used for modifying the chlorella to obtain the polydopamine-coated chlorella Ch (at) P with a photothermal effect, and the Ch (at) P not only maintains the biological activity of the chlorella, but also has the effect of delaying cartilage degeneration and OA process due to the photothermal effect under near infrared (NIR) irradiation.

The present disclosure relates to mesenchymal stem cells (MSCs) for use in a method of treatment of arthritis. The MSCs are transfected with an mRNA construct encoding a pro-chondrogenic and / or chondrocyte protective factor. The pro-chondrogenic and / or chondrocyte protective factor can be WNT3a.

The invention relates to the technical field of biological medicine, and provides application of a dental pulp stem cell exosome in preparation of a medicine for treating and preventing osteoarthritis, a preparation method of the dental pulp stem cell exosome comprises the following steps: S1, obtaining dental pulp tissue from a dental pulp cavity of an in-vitro tooth; s2, pretreating dental pulp tissues, adding digestive juice, digesting, centrifuging, discarding supernatant, adding a complete culture medium containing antibiotics into precipitates, mixing, filtering and centrifuging to obtain dental pulp stem cells; and S3, culturing the dental pulp stem cells by using a complete culture medium, when the confluence degree of the dental pulp stem cells reaches 60-80%, replacing the serum-free culture medium for continuous culture, collecting the dental pulp stem cell conditioned culture medium, and performing differential centrifugation to obtain the dental pulp stem cell exosome. According to the technical scheme, the regulating effect of the dental pulp stem cell exosome on endoplasmic reticulum stress and the mechanism of the dental pulp stem cell exosome for improving cartilage cell degeneration are explored.

The present invention relates to a pharmaceutical composition for treating cartilage damage diseases, comprising, as an active ingredient, magnetic nanoparticle-embedded nasal septal chondrocytes , and establishes a method for embedding magnetic nanoparticles into nasal septal chondrocytes and a method for preparing spheroids by culturing magnetic nanoparticle-embedded nasal septal chondrocytes. It was identified that the magnetic nanoparticle-embedded nasal septal chondrocytes prepared by the method of the present invention and spheroids prepared therefrom exhibit cartilage damage treatment activity while maintaining mobility in a magnetic field. In addition, since the activity is maintained even if spheroids are prepared by mixing magnetic nanoparticle-embedded nasal septal chondrocytes and nasal septal chondrocytes, the present invention can be effectively used as a composition for treating cartilage damage diseases that has an excellent therapeutic effect without causing side effects by having a significantly reduced addition ratio of the magnetic nanoparticles.

Provided are a chondrogenic stem cell for promoting joint repair and use thereof. Specifically, disclosed is a cell preparation used for alleviating or treating osteoarthritis, comprising a Procr-positive pluripotent stem cell. The Procr-positive chondrogenic stem cell can differentiate and generate downstream chondrocytes in vivo and promote cartilage repair in osteoarthritis damage, which will be a more effective cell treatment method. In addition, Procr proteins can be used as a new target of a drug for treating osteoarthritis.

This invention belongs to the field of biomedical technology, specifically relating to the application of bufalin in the preparation of drugs for treating osteoarthritis. The structure of bufalin is shown in the following formula. Research results of this invention show that bufalin can significantly inhibit the inflammatory response and matrix degradation of chondrocytes, protecting the extracellular matrix of chondrocytes, thereby effectively delaying or reversing the pathological progression of osteoarthritis. This invention uses the SW1353 human chondrosarcoma cell line and SD rat primary chondrocytes as in vitro experimental models. The two cell models mutually validated each other, fully demonstrating the protective effect of bufalin on chondrocytes and its potential application value in the treatment of osteoarthritis.

The invention discloses a functional composition capable of improving bone and joint health, a conditioner and application. The functional composition comprises a first active component and a second active component, the first active component is prepared from elastin peptide, haematococcus pluvialis and ergothioneine; the second active component is prepared from one or more of herba houttuyniae and non-denatured type II collagen. Through scientific compatibility of all the components, the levels of glycosaminoglycan in chondrocytes and osteocalcin in osteoblasts are synergistically improved, and the protection effect on joint, cartilage and skeleton health is achieved. Meanwhile, a plurality of components in the functional composition capable of improving the health of the bones and the joints are natural in source, good in biocompatibility and free of obvious side effects, and a medicine or an alternative scheme thereof is provided for treatment and prevention of the bone diseases.